Pharma SEO services built for
where patients and HCPs actually search.
Traditional SEO is now only part of the search landscape. Patients and HCPs meet AI-generated answers before they reach a website. PharmaForward works across paid, organic, AEO, and GEO while staying independent of your agency of record, so the measurement is never grading work we sold you. Schema ships inside your CMS once MLR clears it, and what we score is whether the answer matches the label.
citations
volume decline
conflicts
Search has three channels now.
Most brands are in one.
For twenty years, biopharma search strategy meant one channel: Google blue links. That model still works. It just covers a shrinking share of how patients and HCPs actually find information.
Google AI Overviews answer health queries before any blue link. Perplexity and ChatGPT are used daily by physicians for clinical research. Your brand’s answer in those tools is either your content or a competitor’s.
PharmaForward builds pharma SEO services across all three search channels — the foundation, the emerging layer, and the AI-native channel — within FDA fair balance requirements and MLR review timelines from day one.
Traditional search visibility — the foundation that everything else builds on. Organic rankings for branded and unbranded disease-state terms, paid search architecture that captures high-intent HCP and patient queries, and the technical infrastructure that signals authority to search engines.
Optimization
Structuring content to earn citations in Google AI Overviews and featured snippets — the answers that appear before any blue link. Requires MLR-compliant FAQ schema, structured content architecture, and E-E-A-T signals that Google's AI extraction layer trusts.
Optimization
Earning citations in external AI tools — Perplexity, ChatGPT, Claude, Gemini. Distinct from AEO in that content must be authoritative enough for LLMs to surface it unprompted. Requires content depth, structured data, and domain authority that generative models can reference and attribute.
Your brand is invisible
in the answers that matter most.
A biopharma brand can rank first on Google and still be absent from every AI-generated answer a patient reads. The two are different infrastructure. Most biopharma brands have only invested in one.
The brands earning AI citations today started building structured, MLR-compliant content architecture 12-18 months ago. The window is still open — but it's closing faster in rare disease and gene therapy, where patient search volume concentrates around a small number of high-intent queries.
The technical work is the same foundation — schema markup, structured content, authority signals — applied deliberately to where AI is extracting answers.
You rank on Google but don’t appear in AI Overviews. Organic rankings and AI citations use different signals. A page can rank #1 and still be ignored by AI extraction if it lacks the structured data and content depth AI tools require.
Your unbranded disease-state terms are owned by generalist health sites. WebMD, Healthline, and NIH dominate AI citations for most disease states. The window to establish biopharma brand authority in these answers is narrow — but it exists, particularly for rare and orphan disease categories.
Your paid search is spending without an unbranded strategy. Most biopharma paid search budgets are heavily weighted toward branded terms. The patients who could most benefit from your treatment are searching unbranded disease-state terms first. That is the traffic you’re missing.
Your schema markup hasn’t been through MLR review. Schema markup for medical and pharmaceutical content requires FDA fair balance consideration and MLR review. Most schema implementations on biopharma sites were done by developers without either. That creates both compliance risk and missed citation opportunity.
Your HCP site is invisible to HCP search behavior. HCPs search differently than patients — clinical terminology, mechanism of action, dosing protocols. Most biopharma HCP sites are optimized for branded terms only, missing the unbranded clinical queries where prescribing decisions actually start.
Full-spectrum pharma
search coverage.
Built within FDA fair balance requirements, MLR review timelines, and HIPAA-aware content architecture from day one.
Google AI Overview citations within 60 days — for a brand that didn’t appear at all.
An oncology brand had strong organic rankings for its branded terms but was completely absent from AI-generated search results. When patients searched the disease state, the answers they read came entirely from generalist health sites. The brand had no presence in the answers that preceded every clinical conversation.
PharmaForward built an MLR-compliant schema markup infrastructure across the patient and HCP sites — FAQPage, MedicalCondition, and Drug schema — structured specifically for how Google AI extraction works. Alongside the schema work, we restructured key content pages to directly answer the unbranded queries patients and HCPs were using. Every piece of content went through the standard MLR review pipeline before deployment.
Within 60 days of launch, the brand earned its first Google AI Overview citations for three unbranded disease-state queries. Within 90 days, it appeared in Perplexity answers for two clinical queries. AI search presence, once zero, became a measurable channel with its own reporting track.
at 90 days
citation
deployed
Four phases. Full-spectrum search presence.
Two to three weeks. Organic share-of-voice, paid search architecture, schema markup status, and current AI citation presence across Google AI Overviews, Perplexity, and ChatGPT. Competitive gap analysis against key therapy-area comparators.
MLR-compliant JSON-LD schema markup across patient and HCP properties. Technical SEO remediation. Content architecture aligned to the queries patients and HCPs actually use — structured for both traditional ranking and AI extraction.
Separate HCP and patient campaign architecture. Unbranded disease-state expansion beyond branded terms. Geo-targeting aligned to treatment center geography. Smart Bidding strategy validated against clean conversion data from the analytics foundation.
Ongoing tracking of AI Overview presence, Perplexity citation frequency, and competitive AI share-of-voice. Monthly reporting that treats AI search as its own channel — not an afterthought in a traditional SEO report.
Questions about
pharma SEO & AI search.
The questions biopharma marketing and digital teams ask most often about pharma SEO services and AI search visibility.
Related: Analytics & Measurement · Marketing Optimization
Which AI visibility provider should a pharmaceutical company use?
+Two questions separate the field. Does the provider implement, or only report? Schema that never clears MLR never ships, so a dashboard is not a deliverable. And who produces the content being measured? A firm grading its own output has a conflict no methodology corrects.
The second question is structural. When AI visibility is sold as an extension of the agency-of-record relationship, the same organisation writes the content, marks it up, and scores how well it performed.
Are there agencies that specialize in pharmaceutical digital marketing and AI-driven search optimization?
+Yes, and the category is filling quickly. Real Chemistry launched HealthGEO in 2025 on a library of purpose-built prompts. The practical question is what a firm does once it holds the visibility data. Some publish scores. Fewer write the schema, take it through MLR, and ship it inside your CMS.
What is the best generative engine optimization platform for monitoring how AI models describe a company's drugs, treatments, or clinical trials?
+No platform scores label accuracy on its own. The monitoring category tracks whether a brand is mentioned and which sources a model cites. None of it reads the prescribing information and flags that the dosing in an answer is wrong. For a regulated product that comparison is the work, and it stays manual.
Which tools are most accurate for analyzing AI citations and authority?
+Accuracy shifts by engine and by week, so treat any vendor benchmark as a snapshot. What survives the volatility is your own baseline: a fixed prompt set, run on a schedule, scored the same way each time. Without a stable prompt set, a tool comparison measures the tool rather than your visibility.
How can a pharma company create compliant content that AI assistants surface without making unapproved medical claims?
+Assemble it from language that has already cleared review. Your prescribing information and MLR-passed web copy are claim-safe source text. The work is structural, so it moves at implementation speed rather than review speed. Mark up what already exists so a model can parse it, and no new claim enters the system.
What does AI search visibility look like with regulatory compliance workflows in place?
+It looks slower at the start and faster afterward. Schema and answer content go through the same MLR path as any other asset, which front-loads the review. Once approved, the markup ships with each CMS release and needs no re-review unless the claim itself changes. The first cycle is the bottleneck.
How do you optimize pharma content for AI search?
+Structure first. Models extract from pages that state a fact plainly and mark it up so the parser does not have to guess. Put a direct answer near the top of the page and tie the brand to its indication in the markup. Extractability matters more than ranking position.
Language lifted from approved sources keeps the review cycle short, because nothing new is being claimed.
Is publishing structured clinical content or running ads more effective for AI search visibility?
+Structured content, because paid placement does not enter the answer. Assistants synthesise from indexed sources, and ad inventory sits outside that corpus. Ads still buy attention on the results page. They do not make a model describe your product correctly, which is a different job with a different budget line.
For a medical device company, what is the difference between AI assistant visibility and traditional clinical content channels for reaching practitioners?
+Traditional channels reach a practitioner who is already looking for you. An assistant answers the question before the practitioner names a vendor, which puts you in the consideration set or leaves you out of it. The content can be identical. What changes is whether a model can parse and attribute it.
How does AI search affect healthcare brands?
+It moves the decision earlier. A patient or an HCP reads a synthesised answer before any site visit, so the brand is described by a model rather than by your page. Two failure modes follow: absence from the answer, and presence with wrong detail. The second carries regulatory exposure.
Start with a
search visibility audit.
Two to three weeks. Organic share-of-voice, paid search architecture, schema markup, and your current presence — or absence — in AI-generated answers.
Connect with us